Author

Jakob Axelsson

Institution: BioGaia (Sweden)

Observed institutions: Lund University, BioGaia (Sweden)

ORCID: 0000-0003-4146-8374

Observed ORCID: 0000-0003-4146-8374

OpenAlex ID: A5101403969

Limosilactobacillus reuteri DSM 17938 supplementation and SARS-CoV-2 specific antibody response in healthy adults: a randomized, triple-blinded, placebo-controlled trial

2023 · Richard A. Forsgård, Julia Rode, et al. · Gut Microbes · 24

Treatment with anti-factor VIIa in acute pancreatitis in rats: Blocking both coagulation and inflammation?

2007 · Ellen Andersson, Jakob Axelsson, et al. · Scandinavian Journal of Gastroenterology · 13

Oral Biofilm Composition, Dissemination to Keratinocytes, and Inflammatory Attenuation Depend on Probiotic and Synbiotic Strain Specificity

2024 · Wannes Van Holm, Naiera Zayed, et al. · Probiotics and Antimicrobial Proteins · 8

The effects of a 6-week intervention with Limosilactobacillus reuteri ATCC PTA 6475 alone and in combination with L. reuteri DSM 17938 on gut barrier function, immune markers, and symptoms in patients with IBS-D—An exploratory RCT

2024 · Julia König, María Fernanda Roca Rubio, et al. · PLoS ONE · 6

Genomic, phenotypic, and clinical safety of Limosilactobacillus reuteri ATCC PTA 4659

2023 · Malin Sendelius, Jakob Axelsson, et al. · Journal of Industrial Microbiology & Biotechnology · 3

Daily supplementation with canine-isolated Limosilactobacillus reuteri ATCC PTA 6127 is well tolerated, improves stool consistency, and modulates gut microbiome in dogs

2026 · Danielle N. Rendina, Seth Commichaux, et al. · Frontiers in Veterinary Science

The effects of a 6-week probiotic intervention on gut barrier function, immune markers and symptoms in patients with irritable bowel syndrome

2024 · Julia König, Julia König, et al. · Norsk tidsskrift for ernæring

Works count: 7

Citation count: 54

H-index: 4

I10-index: 2